Related Experiment Video
Updated: Apr 28, 2026

05:52
Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
Published on: June 30, 2011
19.3K
Pen injector for insulin-requiring diabetic patients
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|October 1, 1992
Summary
Pen injectors and traditional syringes showed similar metabolic control for diabetes patients. Patient preference varied, with some finding pen injectors limited by insulin dosage capacity.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Diabetes mellitus management often involves insulin therapy.
- Traditional insulin delivery methods include syringes and vials.
- Pen injectors offer an alternative delivery system for insulin.
Purpose of the Study:
- To compare the metabolic control and patient acceptability of insulin pen injectors versus traditional syringes.
- To evaluate the efficacy of pen injectors in managing diabetes.
Main Methods:
- A randomized cross-over study involving 18 patients (12 non-insulin-dependent diabetes mellitus, 6 insulin-dependent diabetes mellitus).
- Patients used both pen injectors and syringes for 12-week periods.
- Metabolic control assessed via biochemical tests and HbA1c levels.
Main Results:
- No significant difference in metabolic control (HbA1c, blood glucose) between pen injectors and syringes.
- Slight, non-significant decrease in mean blood glucose with both methods.
- Similar rates of hypoglycemia and self-adjusted insulin dosages.
- Patient preference was divided between pen injectors and syringes.
Conclusions:
- Insulin pen injectors and syringes provide comparable metabolic control and safety.
- Patient preference is subjective and may be influenced by factors like insulin resistance.
- A limitation of current pen injectors is the maximum insulin dose per injection, which may not suit all patients, particularly those with insulin resistance.
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
205
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
205
Insulin: Biosynthesis, Chemistry, and Preparation
2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Production of Pharmaceuticals
90
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
90

